Pascal Qian

Dear Fellow AmCham China Members,

My name is Pascal Qian, and I currently serve as Vice President of Bristol Myers Squibb, and General Manager of Bristol Myers Squibb for China. Prior to joining Bristol Myers Squibb, I served as Chief Commercial Officer and General Manager for China at LianBio, and several senior leadership roles at multinational pharmaceutical companies such as Eli Lilly, Novartis, and Pfizer.

I would like to express my keen interest in being considered for a position on the 2026 Board of Governors of AmCham China. By serving in this capacity, I aim to make meaningful contributions to the success of AmCham and the broader U.S. business community in China during this pivotal time.

With nearly 30 years of extensive experience in the biopharmaceutical industry, I’ve accumulated a wealth of experience in various pharmaceutical functions. Drawing on my clinical medicine expertise, I collaborate with industry thought leaders to gain a deeper understanding of patient needs and expedite the development of new products. Through leadership positions on association boards — including the US-China Anti-Cancer Association (USCACA), Vice Chairman of the Clinical Research Committee of the Chinese Society of Clinical Oncology (CSCO), and the Hangzhou Clinical Oncology Research Association — I obtain valuable perspectives on both the challenges and opportunities involved in research and development.

I also firmly hold the conviction that obtaining regulatory approval merely represents the initial milestone, and it is only when these innovative drugs are accessible to patients that their genuine worth and potential can be fully actualized. I have had the privilege of participating in the first National Reimbursement Drug List (NRDL) negotiation and have since witnessed, over the past several years, how the expanded access to medications has significantly benefited millions of patients across China. As the GM of BMS, I am very proud to see that four of our innovative products have been included in the National Reimbursement Drug List within one year of their approval over the last few years. With our full supports to the new 1+3+N system, we are also very eager to explore a more innovative multi-tiered medical security system by better integrating basic medical insurance, commercial medical insurance, and patient assistance programs, etc.

In addition, I have consistently demonstrated strong support for innovative business development initiatives and collaborative endeavors. China has evolved beyond being merely a market; it has now become an innovation ecosystem. The new therapeutic needs of Chinese patients, the Chinese government’s continuous enhancement of innovation policies, the clinical research capabilities of Chinese researchers will all increasingly underscore the ecosystem’s growing significance on a global scale. I also maintain close collaboration with the China Pharmaceutical Innovation and Research Development Association (PhIRDA), along with various other local organizations. Our joint efforts are dedicated to uncovering promising opportunities for research and business development partnerships that extend beyond the scope of “In China, For China” to encompass a broader vision of “In China, For Global” initiatives.

In my professional capacity, I also maintain close collaboration with organizations such as  Pharmaceutical Research and Manufacturers of America (PhRMA) and the China Association of Enterprises with Foreign Investment (CAEFI) to address prevailing challenges facing the pharmaceutical industry and foreign investment in China. Our collective efforts focus on reinforcing the importance of cultivating a stable and investment-friendly business environment, which is crucial for the long-term success of multi-national companies operating in China.

As a healthcare enterprise with a sustained operational presence and long-term dedication to China, we hold AmCham China in high esteem for its unwavering commitment to safeguarding and advancing the interests of the U.S. business community in China. I firmly believe that a stable and constructive U.S.-China relationship is of paramount importance for the sustained success of our businesses. Amidst an increasingly intricate and interconnected global environment, the role of AmCham as the representative voice of the American business community has never been more indispensable.

In conclusion, if given this opportunity, I pledge to fervently champion our collective interests as a steadfast and trustworthy partner. Your support in this endeavor would be immensely valued.

Sincerely,

Pascal Qian